;

Bicycle Therapeutics Secures an Innovate UK Grant to Develop Next Generation Antibiotics

04/01/2018

Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) product platform, announced today that it has been awarded a grant from Innovate UK, the UK’s innovation agency, to apply Bicycle technology to develop the next generation of novel antibiotics.

Bicycles are a new therapeutic modality that combine high affinity and exquisite selectivity in a chemically synthesized format. The Innovate UK funding will be used to develop Bicycles with unique properties and novel mechanisms of anti-bacterial action. Dr. Mike Dawson, former Chief Executive Officer of Cantab Anti-Infectives and a seasoned industry expert with 30 years of expertise in infectious disease drug discovery and development, will lead the project. Formerly, Mike spent 20 years at GSK, where he led the natural product chemistry and biotransformations programs contributing to the development of three marketed antiviral agents as well as multiple clinical stage antibacterials and antifungals. Subsequently he co-founded Novacta Biosystems, where he led the NVB302 program from concept to clinic for C. difficile infection.

“This competitive and peer-reviewed award builds on our strategy to explore the utility for Bicyclesbeyond oncology using non-dilutive funding. It also provides further validation of the versatility of the Bicycle platform and its broad potential for application across all therapy areas, including anti-bacterials,” said Kevin Lee, Ph.D., Chief Executive Officer of Bicycle Therapeutics. “Bicycles are structurally highly similar to many commonly prescribed natural product cyclic peptide antibiotics. Our enormously diverse compound library and highly efficient optimized screening approach will allow us to generate next generation antibiotics. We are grateful to Innovate UK for their vote of confidence and are looking forward to working with Mike Dawson to advance a much-needed novel approach in this extremely important area of research.”

“New anti-infective products are desperately needed to combat the rapidly growing threat of antimicrobial resistance, an area of critical unmet medical need,” said Dr. Dawson. “The antibiotics field has seen little innovation in recent years, with just three new classes of antibiotics introduced during the past 40 years. I am delighted to be collaborating with Bicycle to advance this exciting work. The funding from Innovate UK will enable our team to make important progress in advancing a truly innovative, and potentially transformative, approach to treating infectious diseases.”

Click here for full press release

Contact us

BABRAHAM RESEARCH
CAMPUS

(+44) 1223 496 000
info@babraham.co.uk

Babraham Bioscience Technologies Ltd
Babraham Research Campus
Cambridge
CB22 3AT, United Kingdom

Press Enquiries

Limewash
01223 813 557
info@limewash.co.uk

Subscribe to our mailing list

Please enter your first name
Please enter your surname
Please enter your email address
Submit
; ;